(CRON) Cronos - Ratings and Ratios
Cannabis, Edibles, Oils, Vapes, Topicals
CRON EPS (Earnings per Share)
CRON Revenue
Description: CRON Cronos August 27, 2025
Cronos Group Inc. (NASDAQ:CRON) is a Canada‑based publicly traded entity operating in the cannabis segment, classified under GICS Pharmaceuticals. The market values the company at roughly $954 million, with the share price trading at $2.55, marginally above its 20‑day SMA ($2.39) and well above the 200‑day SMA ($1.99), indicating short‑term upward pressure. A beta of 1.5 signals amplified sensitivity to market movements.
The current price‑to‑earnings ratio stands at 49.6, while the forward P/E is undefined, reflecting a lack of positive earnings guidance. Return on equity is 1.66 %, underscoring minimal profitability on shareholder capital. Historical volatility is evident from a 5.29 % ATR and a 52‑week price range of $1.62–$2.67.
Key performance indicators for Cronos include annual revenue growth of approximately 30 % YoY (2023), EBITDA consistently negative, and net cash burn exceeding $300 million per year. Cash reserves sit near $600 million, providing a runway of roughly two years absent external financing. Debt‑to‑equity remains low (<0.2), but the capital structure is heavily weighted toward equity financing.
Primary economic drivers are regulatory developments in North America, particularly U.S. federal cannabis legalization prospects, which could expand addressable market size from $30 billion to $100 billion. Canadian domestic consumption trends, pricing compression, and supply‑side overcapacity exert downward pressure on margins. Strategic partnership with Altria supplies both capital infusion and distribution leverage, but also ties performance to Altria’s execution risk.
Operational levers for value creation are limited to accelerating product launches, improving cost‑of‑goods‑sold efficiency, and securing higher‑margin wholesale contracts. Absent a shift to positive EBITDA, the stock’s valuation hinges on speculative upside from regulatory breakthroughs rather than fundamental earnings momentum.
CRON Stock Overview
| Market Cap in USD | 963m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2016-07-12 |
CRON Stock Ratings
| Growth Rating | -1.56% |
| Fundamental | 37.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -7.20% |
| Analyst Rating | 3.40 of 5 |
CRON Dividends
Currently no dividends paidCRON Growth Ratios
| Growth Correlation 3m | -19.6% |
| Growth Correlation 12m | 53.2% |
| Growth Correlation 5y | -76.7% |
| CAGR 5y | -3.69% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.07 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.10 |
| Sharpe Ratio 12m | -2.14 |
| Alpha | -16.92 |
| Beta | 1.644 |
| Volatility | 43.95% |
| Current Volume | 1245.5k |
| Average Volume 20d | 1327k |
| Stop Loss | 2.3 (-6.1%) |
| Signal | -0.27 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (17.8m TTM) > 0 and > 6% of Revenue (6% = 8.46m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -1.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 630.5% (prev 881.8%; Δ -251.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 20.2m > Net Income 17.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 24.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (385.3m) change vs 12m ago 0.82% (target <= -2.0% for YES) |
| Gross Margin 30.24% (prev 15.81%; Δ 14.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 12.45% (prev 9.38%; Δ 3.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.80 (EBITDA TTM -60.6m / Interest Expense TTM -92.6m) >= 6 (WARN >= 3) |
Altman Z'' 30.98
| (A) 0.76 = (Total Current Assets 927.1m - Total Current Liabilities 37.6m) / Total Assets 1.18b |
| (B) 0.36 = Retained Earnings (Balance) 424.1m / Total Assets 1.18b |
| (C) -0.07 = EBIT TTM -73.8m / Avg Total Assets 1.13b |
| (D) 24.07 = Book Value of Equity 1.08b / Total Liabilities 45.0m |
| Total Rating: 30.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 37.64
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -7.14% = -3.57 |
| 3. FCF Margin -6.60% = -2.48 |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda 13.07 = -2.50 |
| 6. ROIC - WACC (= -18.83)% = -12.50 |
| 7. RoE 1.66% = 0.14 |
| 8. Rev. Trend 89.83% = 6.74 |
| 9. EPS Trend 46.13% = 2.31 |
What is the price of CRON shares?
Over the past week, the price has changed by -0.41%, over one month by -3.92%, over three months by +18.93% and over the past year by +10.36%.
Is Cronos a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRON is around 2.11 USD . This means that CRON is currently overvalued and has a potential downside of -13.88%.
Is CRON a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CRON price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.1 | -15.9% |
| Analysts Target Price | 2.1 | -15.9% |
| ValueRay Target Price | 2.4 | -1.2% |
CRON Fundamental Data Overview November 04, 2025
P/E Trailing = 50.2
P/S = 7.3912
P/B = 0.9164
Beta = 1.644
Revenue TTM = 141.1m USD
EBIT TTM = -73.8m USD
EBITDA TTM = -60.6m USD
Long Term Debt = 2.01m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 822.0k USD (from shortTermDebt, last quarter)
Debt = 2.01m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -792.4m USD (from netDebt column, last quarter)
Enterprise Value = 130.5m USD (962.9m + Debt 2.01m - CCE 834.4m)
Interest Coverage Ratio = -0.80 (Ebit TTM -73.8m / Interest Expense TTM -92.6m)
FCF Yield = -7.14% (FCF TTM -9.31m / Enterprise Value 130.5m)
FCF Margin = -6.60% (FCF TTM -9.31m / Revenue TTM 141.1m)
Net Margin = 12.64% (Net Income TTM 17.8m / Revenue TTM 141.1m)
Gross Margin = 30.24% ((Revenue TTM 141.1m - Cost of Revenue TTM 98.4m) / Revenue TTM)
Gross Margin QoQ = 32.78% (prev 42.57%)
Tobins Q-Ratio = 0.11 (Enterprise Value 130.5m / Total Assets 1.18b)
Interest Expense / Debt = 401.5% (Interest Expense 8.07m / Debt 2.01m)
Taxrate = 1.37% (-533.6k / -39.0m)
NOPAT = -72.8m (EBIT -73.8m * (1 - 1.37%)) [loss with tax shield]
Current Ratio = 24.65 (Total Current Assets 927.1m / Total Current Liabilities 37.6m)
Debt / Equity = 0.00 (Debt 2.01m / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = 13.07 (negative EBITDA) (Net Debt -792.4m / EBITDA -60.6m)
Debt / FCF = 85.08 (negative FCF - burning cash) (Net Debt -792.4m / FCF TTM -9.31m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.52% (Net Income 17.8m / Total Assets 1.18b)
RoE = 1.66% (Net Income TTM 17.8m / Total Stockholder Equity 1.07b)
RoCE = -6.86% (EBIT -73.8m / Capital Employed (Equity 1.07b + L.T.Debt 2.01m))
RoIC = -6.78% (negative operating profit) (NOPAT -72.8m / Invested Capital 1.07b)
WACC = 12.04% (E(962.9m)/V(965.0m) * Re(12.07%) + (debt cost/tax rate unavailable))
Discount Rate = 12.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.54%
Fair Price DCF = unknown (Cash Flow -9.31m)
EPS Correlation: 46.13 | EPS CAGR: 405.2% | SUE: -0.25 | # QB: 0
Revenue Correlation: 89.83 | Revenue CAGR: 31.31% | SUE: -0.22 | # QB: 0
Additional Sources for CRON Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle